ZIM
MXCT icon

Zacks Investment Management’s MaxCyte MXCT Stock Holding History

Zacks Investment Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,976
Closed -$26.1K – 812
2025
Q2 		$26.1K Buy
+11,976
New +$29K ﹤0.01% 691

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zacks Investment Management's MXCT Position: Q3 2025 in Review

Zacks Investment Management sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 11,976 shares — an estimated $26.1K sold.

Zacks Investment Management first reported a position in MXCT in Q2 2025 and held it in 1 quarter. The position peaked at $26.1K in Q2 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • Zacks Investment Management reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 11,976 MaxCyte shares in Q3 2025, an estimated $26.1K.
  • Zacks Investment Management first reported a position in MaxCyte in Q2 2025 and held it in 1 quarter.
  • Zacks Investment Management's MaxCyte position peaked at $26.1K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.